The combination of ibrutinib and venetoclax has shown synergism in preclinical models of MCL with enhanced levels of dephosphorylation of substrates within the BTK pathway as well as a reduction in levels of anti-apoptotic BCL2 family members [83]. Here, BCL2 is linked to mantle cell lymphoma.